These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6714293)

  • 1. The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon.
    Kitteringham NR; Büstgens L; Brundert E; Mineshita S; Ohnhaus EE
    Eur J Clin Pharmacol; 1984; 26(1):65-70. PubMed ID: 6714293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of wheat bran on the pharmacokinetics of phenprocoumon in normal volunteers.
    Kitteringham NR; Mineshita S; Ohnhaus EE
    Klin Wochenschr; 1985 Jun; 63(12):537-9. PubMed ID: 2993733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between phenprocoumon and phytomenadion: a pharmacokinetic investigation in healthy volunteers.
    Haustein KO
    Biomed Biochim Acta; 1984; 43(12):1417-24. PubMed ID: 6534380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine.
    Meinertz T; Gilfrich HJ; Groth U; Jonen HG; Jähnchen E
    Clin Pharmacol Ther; 1977 Jun; 21(6):731-5. PubMed ID: 862312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans.
    Heimark LD; Toon S; Gibaldi M; Trager WF; O'Reilly RA; Goulart DA
    Clin Pharmacol Ther; 1987 Sep; 42(3):312-9. PubMed ID: 3621786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Elimination kinetics of phenprocoumon (Marcumar) in liver cirrhosis and after premedication with phenobarbital].
    Heni N; Lehnhardt G; Glogner P
    Int J Clin Pharmacol Biopharm; 1976 Jun; 13(4):253-61. PubMed ID: 965132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Separation of the enantiomers of phenprocoumon and warfarin by high-performance liquid chromatography using a chiral stationary phase. Determination of the enantiomeric ratio of phenprocoumon in human plasma and urine.
    de Vries JX; Völker U
    J Chromatogr; 1989 Aug; 493(1):149-56. PubMed ID: 2778004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats.
    Schmidt W; Jähnchen E
    J Pharm Pharmacol; 1977 May; 29(5):266-71. PubMed ID: 17688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic fate of phenprocoumon in humans.
    Toon S; Heimark LD; Trager WF; O'Reilly RA
    J Pharm Sci; 1985 Oct; 74(10):1037-40. PubMed ID: 4078699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of induction and inhibition of drug metabolism on pharmacokinetics and anticoagulant activity of the enantiomers of phenprocoumon in rats.
    Schmidt W; Trenk D; Jähnchen E
    Pharmacology; 1980; 21(5):313-22. PubMed ID: 7433511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon.
    Mönig H; Baese C; Heidemann HT; Ohnhaus EE; Schulte HM
    Br J Clin Pharmacol; 1990 Jul; 30(1):115-8. PubMed ID: 2390422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cholestyramine interrupts the enterohepatic circulation of phenprocoumon: a new therapeutic possibility in the treatment of phenprocoumon overdose].
    Meinertz T; Jähnchen E; Gilfrich HJ; Groth U; Jonen HG
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1582-4. PubMed ID: 347787
    [No Abstract]   [Full Text] [Related]  

  • 14. [Probenecid affects liver metabolism].
    Bammel A; Mönig H; Zurborn KH; Ohnhaus EE; Kirch W
    Schweiz Med Wochenschr; 1989 Dec; 119(50):1831-4. PubMed ID: 2609138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of pindolol in liver disease.
    Ohnhaus EE; Münch U; Meier J
    Eur J Clin Pharmacol; 1982; 22(3):247-51. PubMed ID: 7106158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Observations in phenprocoumon (Marcumar) poisoning. Elimination and serum binding of the anticoagulant atatoxic blood concentration].
    Held H; von Busse G; Meissner J
    Dtsch Med Wochenschr; 1980 Jun; 105(24):860-3. PubMed ID: 7418621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.
    Schmidt W; Jähnchen E
    J Pharmacokinet Biopharm; 1979 Dec; 7(6):643-63. PubMed ID: 529027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual variation in the response to phenprocoumon.
    Husted S; Andreasen F
    Eur J Clin Pharmacol; 1977; 11(5):351-8. PubMed ID: 880974
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of frusemide and probenecid on the pharmacokinetics of phenprocoumon.
    Mönig H; Böhm M; Ohnhaus EE; Kirch W
    Eur J Clin Pharmacol; 1990; 39(3):261-5. PubMed ID: 2257863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.